Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 3.9B 3.65B 3.34B 6.26B 435B 6.35B 43.08B 16.8B 219B 17.08B 16.71B 723B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.02B 3.77B 3.45B 6.47B 450B 6.56B 44.49B 17.35B 226B 17.64B 17.26B 747B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+1.05%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.4
Extreme 7.4
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Fiscal year

Chief Executive Officer

225,000 0.0727%
2/1/26 Tax

General Counsel

43,109 0.0139%
2/1/26 Tax

Executive/Senior Manager

30,007 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+90.66%+14.82% 4.55B
+1.09%+5.26%+4.44%+26.03% 51.61B
-1.07%+2.82%+474.18%+601.24% 44.89B
+1.47%+9.79%+40.15%+21.21% 42.77B
+1.44%+7.77%+19.27%+90.94% 42.58B
-0.93%-4.33%+17.87%+51.96% 31.82B
+1.32%+7.30%+36.93%+152.36% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 14.09B
Average +0.42%+4.01%+86.85%+115.66% 28.1B
Weighted average by Cap. +0.48%+4.64%+102.36%+146.22%

Financials

2024 2025
Net sales 528M 453M 423M 388M 727M 50.55B 737M 5B 1.95B 25.39B 1.98B 1.94B 83.99B 634M 543M 508M 465M 873M 60.68B 885M 6.01B 2.34B 30.48B 2.38B 2.33B 101B
Net income -56.11M -48.06M -44.97M -41.16M -77.25M -5.37B -78.27M -531M -207M -2.7B -211M -206M -8.92B -27.11M -23.22M -21.73M -19.89M -37.33M -2.59B -37.82M -257M -100M -1.3B -102M -99.58M -4.31B
Net Debt 194M 166M 155M 142M 267M 18.53B 270M 1.83B 715M 9.31B 727M 711M 30.79B 149M 127M 119M 109M 205M 14.24B 208M 1.41B 550M 7.15B 559M 547M 23.66B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock